Regeneron Pharmaceuticals (NASDAQ:REGN) Hits New 12-Month High at $1,209.18

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s share price reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $1,209.18 and last traded at $1,208.04, with a volume of 42427 shares changing hands. The stock had previously closed at $1,199.37.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Piper Sandler lifted their price target on Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the company an “overweight” rating in a report on Friday. Argus lifted their price target on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a “buy” rating in a report on Tuesday, June 25th. Barclays lifted their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Morgan Stanley dropped their price objective on Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. Finally, Evercore ISI initiated coverage on Regeneron Pharmaceuticals in a report on Tuesday, May 14th. They set an “outperform” rating and a $1,150.00 price objective for the company. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, sixteen have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $1,108.45.

Regeneron Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44. The company has a 50-day moving average of $1,091.14 and a 200-day moving average of $1,006.29. The firm has a market capitalization of $132.42 billion, a price-to-earnings ratio of 35.50, a price-to-earnings-growth ratio of 3.12 and a beta of 0.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The business had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.38 billion. During the same period in the previous year, the firm earned $8.79 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 12.3% compared to the same quarter last year. As a group, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current fiscal year.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CEO Leonard S. Schleifer sold 787 shares of the business’s stock in a transaction that occurred on Thursday, June 6th. The stock was sold at an average price of $1,015.02, for a total value of $798,820.74. Following the sale, the chief executive officer now owns 64,198 shares in the company, valued at approximately $65,162,253.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total value of $105,924.00. Following the sale, the director now owns 17,882 shares in the company, valued at approximately $18,941,329.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Leonard S. Schleifer sold 787 shares of the business’s stock in a transaction that occurred on Thursday, June 6th. The shares were sold at an average price of $1,015.02, for a total value of $798,820.74. Following the completion of the sale, the chief executive officer now owns 64,198 shares in the company, valued at approximately $65,162,253.96. The disclosure for this sale can be found here. In the last three months, insiders sold 16,559 shares of company stock worth $17,087,606. 7.48% of the stock is owned by company insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. New Wave Wealth Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $385,000. New Century Financial Group LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $313,000. 3Chopt Investment Partners LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $565,000. Kimelman & Baird LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $57,000. Finally, B. Riley Wealth Advisors Inc. raised its stake in shares of Regeneron Pharmaceuticals by 8.0% during the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 1,086 shares of the biopharmaceutical company’s stock worth $1,142,000 after purchasing an additional 80 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.